Drug name | Type of agent | Target | Supporting study | Year approved | FDA-approved use on first approval |
Ipilimumab | ICI | CTLA-4 | NCT00094653 | 2011 | Melanoma |
Pembrolizumab | ICI | PD-1 | KEYNOTE-001 (NCT01295827) | 2014 | Melanoma |
Nivolumab | ICI | PD-1 | CheckMate 037 (NCT01721746) | 2014 | Melanoma |
Cemiplimab | ICI | PD-1 | Study 1423 (NCT02383212), Study 1540 (NCT02760498) | 2018 | Cutaneous squamous cell carcinoma |
Atezolizumab | ICI | PD-L1 | NCT02108652 | 2016 | Urothelial carcinoma |
Avelumab | ICI | PD-L1 | JAVELIN Merkel 200 (NCT02155647) | 2017 | Merkel cell carcinoma |
Durvalumab | ICI | PD-L1 | Study 1108 (NCT01693562) | 2017 | Urothelial carcinoma |
Tisagenlecleucel | CAR T cell | CD19 | ELIANA (NCT02435849) | 2017 | B cell precursor acute lymphoblastic leukemia |
Axicabtagene ciloleucel | CAR T cell | CD19 | ZUMA-1 (NCT02348216) | 2017 | Large B cell lymphoma |
Sipuleucel-T | Vaccine | Prostatic acid phosphatase | IMPACT (NCT00065442) | 2010 | Castration-resistant prostate cancer |
Talimogene laherparepvec | Oncolytic virus | Tumor cells | OPTiM (NCT00769704) | 2015 | Melanoma |
CAR T cell, chimeric antigen receptor T cell; CTLA-4, cytotoxic T lymphocyte-associated protein-4; FDA, Food and Drug Administration; ICI, immune checkpoint inhibitor; PD-1, programmed cell death protein-1; PD-L1, programmed death-ligand 1.